ARTICLES LIST

Clear Search

Select the Article Source National Cancer Institute Office of Dietary Supplements National Institute on Aging Healthfinder.gov National Institute of Child Health and Human Development Centers for Disease Control and Prevention Administration for Children and Families National Institute of Environmental Health Sciences National Library of Medicine National Institute of Allergy and Infectious Diseases National Center for Complementary and Integrative Health National Institute of Neurological Disorders and Stroke NIH Senior Health National Institute of Arthritis and Musculoskeletal and Skin Diseases Health and Human Services National Institute of General Medical Sciences National Institute of Dental and Craniofacial Research National Human Genome Research Institute Food and Drug Administration Center for Tobacco Products Public Health and Medical Emergency Support for a Nation Prepared Office of Disease Prevention and Health Promotion, Healthy People National Institute on Drug Abuse National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases U S Food and Drug Administration National Institute on Deafness and Other Communication Disorders National Heart, Lung, and Blood Institute

Media ID	Source Name	Media Type	Language	Media Name	Media Description	Keywords	Keywords	Link to Article
1402	National Cancer Institute	Html	en	Childhood Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version	Expert-reviewed information summary about the treatment of childhood non-Hodgkin lymphoma.	T-cell lymphoblastic lymphoma 0.616756 mediastinal B-cell lymphoma 0.654258 Pediatric Non-Hodgkin Lymphoma 0.567507 mature B-cell 0.675642 Engl J Med 0.525188 B-cell non-Hodgkin lymphoma 0.746462 children 0.65412 mature B-cell leukemia 0.544897 cell lymphoma outcome 0.543686 lymphoblastic lymphoma stage 0.540387 pediatric-type follicular lymphoma 0.574777 large B-cell lymphomas 0.528398 large cell lymphoma 0.779097 pediatric anaplastic lymphoma 0.540067 adolescents 0.539146 Burkitt lymphoma 0.638477 mediastinal large B-cell 0.573557 childhood B-cell non-Hodgkin 0.52722 diffuse large b-cell 0.665879 anaplastic large-cell lymphoma 0.616485 center-derived B-cell lymphoma 0.609426 Burkitt lymphoma incidence 0.577758 cell lymphoma cases 0.534062 Leuk Lymphoma 0.529329 large B-cell lymphoma 0.815777	cell lymphoma patients 0.528087 mature B-cell lymphoma 0.609056 et al. 0.801373 Br J Haematol 0.629196 Cairo MS 0.571856 primary mediastinal B-cell 0.5557 Pediatr Blood Cancer 0.817055 childhood B-cell 0.532059 diffuse large-B-cell lymphoma 0.523303 Secondary non-Hodgkin lymphoma 0.572995 mature B-cell non-Hodgkin 0.643468 lymphoblastic lymphoma 0.618923 Abstract 0.750082 cancer group 0.553869 lymphoma 0.902345 Clin Oncol 0.644225 childhood non-Hodgkin lymphoma 0.549011 high-stage Burkitt lymphoma 0.543865 B-cell lymphoma subgroups 0.565819 non-hodgkin lymphoma 0.766463 recurrent non-Hodgkin lymphoma 0.543912 anaplastic large cell 0.660109 oncology group 0.53775 Burkitt-like lymphoma 0.528197	CLICK HERE
1435	National Cancer Institute	Html	en	Childhood Extracranial Germ Cell Tumors Treatment (PDQ®)–Patient Version	Expert-reviewed information summary about the treatment of childhood extracranial germ cell tumors.	testicular germ cell 0.206027 treatment 0.243869 germ cell tumors 0.902772 stage 0.204984 extracranial germ cell 0.708761	ovarian germ cell 0.212137 childhood extracranial germ 0.398861 cancer 0.399843 clinical trials 0.265215	CLICK HERE
1568	National Cancer Institute	Html	en	Gastrointestinal Carcinoid Tumors Treatment (PDQ®)–Patient Version	Expert-reviewed information summary about the treatment of gastrointestinal carcinoid tumors.	carcinoid tumor cells 0.278965 metastatic GI carcinoid 0.238039 treatment 0.556764 cancer treatment 0.277356 malignant tumor cells 0.240006 general information 0.281992 GI carcinoid tumors 0.692008 Hormone therapy 0.212489 Lung Cancer Treatment 0.223918 NCI-supported cancer 0.254433 cancer cells 0.281516 stomach 0.228344 hepatic artery 0.21097 body 0.300003 type 0.211866 PDQ cancer information 0.277061 clinical trial search 0.358585 carcinoid tumor spreads 0.266506 treatment clinical trials 0.240478 recurrent GI carcinoid 0.223511 National Cancer Institute 0.243506 clinical trials 0.834392 tumor cells 0.308788	Carcinoid Tumors Treatment 0.268829 cancer information summary 0.243151 clinical trial 0.501578 new treatment 0.293328 Rectal Cancer Treatment 0.224504 liver 0.203338 gastrointestinal carcinoid tumor 0.314953 patients 0.237822 carcinoid heart syndrome 0.215848 carcinoid tumor tissue 0.264996 carcinoid syndrome 0.334872 metastatic tumor 0.206035 blood 0.210445 cancer clinical trials 0.359168 lymph nodes 0.28707 carcinoid tumors 0.943574 radiation therapy 0.236209 internal radiation therapy 0.21238 cancer 0.673084 information 0.294151 small intestine 0.264836 gastrointestinal carcinoid tumors 0.573326 Intestine Cancer Treatment 0.236505	CLICK HERE
1678	National Cancer Institute	Html	en	Communication in Cancer Care (PDQ®)–Health Professional Version	Effective cancer communication between the health care team, cancer patients, and their family is important. Learn about communication skills that support a patient-centered practice and how to talk with adults and children about their diagnosis, prognosis, and transition to end-of-life care in this expert-reviewed summary.	female breast cancer 0.57505 eligible patients 0.564938 bad news 0.743613 medical decision making 0.58503 physicians 0.592367 direct patient care 0.564892 diverse cancer patients 0.603459 clinical trials 0.61877 communication 0.630971 early-stage breast cancer 0.592631 patients cultural beliefs 0.582353 breast cancer experience 0.564126 breast cancer treatment 0.579002 breast cancer patients 0.646574 patients 0.906881 cancer patients 0.64886 white patients 0.564203 cancer diagnosis 0.569139 health care costs 0.565569 cancer patients report 0.596785 decision making 0.744128 breast cancer therapy 0.566081 treatment decision making 0.568266 older breast cancer 0.566807 care 0.590659	treatment 0.626966 American oncology patients 0.58299 study 0.656108 patient communication preferences 0.600601 cancer disclosure issues 0.56732 African American patients 0.584216 different information styles 0.572854 Asian American women 0.565505 patient decision making 0.57769 black patients 0.564183 younger patients 0.563325 high information needs 0.57343 health care 0.579997 patient information style 0.59028 older patients 0.579527 initial cancer diagnosis 0.562722 Cancer care 0.562573 breast cancer 0.780881 specific treatment information 0.578443 patient satisfaction 0.579033 information patients 0.586119 treatment options 0.585641 rural American patients 0.584504 pessimistic information people 0.566128	CLICK HERE
1830	National Cancer Institute	Html	es	Tratamiento de la leucemia mielógena crónica (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos acerca del tratamiento de la leucemia mielógena crónica.	imatinib treatment 0.309815 associated with 0.307718 Saglio G 0.311488 Imatinib plus 0.308886 mayoría imatinib 0.309903 with chronic myeloid 0.371977 Sin embargo 0.315782 Kantarjian HM 0.372759 standard-dose imatinib therapy 0.309084 myeloid leukemia patients 0.32923 Cortes JE 0.313764 chronic myeloid leukemia 0.996248 or imatinib 0.327327 myelogenous leukemia patients 0.309285 Philadelphia chromosome-positive 0.307544 TCM alogénico 0.343658 chronic myelomonocytic leukemia 0.306491 patients with chronic 0.376511 Rosti G 0.305694 leucemia mielógena 0.3214 stem cell transplantation 0.309631 chronic myelogenous leukemia 0.537094 with imatinib 0.31893 Guilhot F 0.305867 vs imatinib 0.308365	Chronic Leukemia 0.308312 Versus Imatinib Study 0.318542 patients with philadelphia 0.308802 dasatinib or imatinib 0.311418 versus imatinib 0.331295 Jabbour E 0.308732 patients with 0.421072 myeloid leukemia treated 0.313347 Treatment-Naïve Chronic Myeloid 0.309823 marrow transplantation 0.313614 leukemia treated with 0.314928 Dasatinib Versus Imatinib 0.321251 bone marrow transplantation 0.310388 Leukemia Patients Trial 0.308496 newly diagnosed chronic 0.341689 treated with imatinib 0.310526 imatinib depends 0.308315 imatinib versus 0.310194 chronic granulocytic leukemia 0.306345 tirosina cinasa 0.443764 Clin Oncol 0.407181 bone marrow 0.312247 myelogenous leukemia with 0.307043 treated with 0.317153	CLICK HERE
1834	National Cancer Institute	Html	es	Tratamiento del cáncer de células renales (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos acerca del tratamiento del cáncer de células renales.	vena cava 0.123516 renal carcinoma 0.159056 Compton CC 0.125724 renal-cell carcinoma 0.14068 pazopanib versus sunitinib 0.125846 Sin embargo 0.110933 único tratamiento 0.110403 advanced renal 0.148043 7th ed 0.125599 randomized phase 0.121201 pelvis renal 0.120181 Escudier B 0.130262 dekernion jb 0.116071 patients with advanced 0.115714 nefrectomía citorreductora 0.116589 determinados pacientes 0.124987 Kidney Cancer 0.108755 metastatic renal cell 0.258997 metastatic renal carcinoma 0.150259 meses vs 0.112102 nefrectomía contralateral 0.112298 with metastatic renal 0.190502 Urol Clin North 0.118145 patients with metastatic 0.181521 single-center experience with 0.110273	lymphokine-activated killer cells 0.109085 cell carcinoma with 0.117134 determinados pacientes sobrevivirán 0.111069 metastatic renal 0.292754 Cancer Staging Manual 0.154868 National Cancer Institute 0.108824 advanced or metastatic 0.109154 advanced renal-cell carcinoma 0.125408 vena renal 0.12378 New York 0.121032 renal cell cancer 0.159738 cell carcinoma invading 0.114504 Clin Oncol 0.183599 Clin North Am 0.116365 or metastatic renal 0.109426 with advanced renal 0.117403 Byrd DR 0.123857 metastatic renal-cell carcinoma 0.127732 Tomczak P 0.112446 renal cell carcinoma 0.996231 Renal Pelvis Cancer 0.111495 células renales 0.815564 compared with 0.113419 AJCC Cancer Staging 0.157448	CLICK HERE
1901	National Cancer Institute	Html	es	Tratamiento del glioma de tronco encefálico infantil (PDQ®)–Versión para pacientes	Resumen de información revisada por expertos acerca del tratamiento del glioma de tronco encefálico infantil.	siguientes procedimientos 0.461896 IRM periódicas 0.425856 posibles factores 0.428641 efectos secundarios meses 0.538429 encéfalo benignos 0.484108 pontino intrínseco difuso 0.901206 efectos tardíos 0.636065 PDQ Efectos tardíos 0.495055 National Cancer Institute 0.428512 sustancia llamada gadolinio 0.454314 siguientes riesgos 0.420658 llamada neurofibromatosis tipo 0.456821 Instituto Nacional 0.447041 cinasa braf 0.631095 presente sumario 0.527425 PDQ Tratamiento 0.518077	determinados cambios 0.420201 neurofibromatosis tipo 0.564203 nuevos tipos 0.430533 sistema nervioso central 0.564289 Physician Data Query 0.500648 proteína braf 0.427497 Aboutâ„¢ Brain Tumors 0.435067 tumor dipg 0.504754 siguientes enlaces 0.422666 encefálico infantil recién 0.732248 panel derecho 0.429689 cuidado paliativo 0.460842 siguientes sumarios 0.465406 largo tiempo 0.418821 siguientes trastornos 0.430211	CLICK HERE
2039	National Cancer Institute	Html	es	Exámenes de detección del cáncer de piel (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos acerca de las pruebas utilizadas para detectar sistemáticamente el cáncer de piel.	skin cancer 0.943888 pediatric melanoma 0.526248 cutaneous melanoma 0.524708 incidence estimate 0.432333 pediatric melanoma mortality 0.475024 Waldmann A 0.448643 pruebas directas 0.467472 accessed october 0.431704 American Cancer Society 0.752465 largo plazo 0.427741 incidencia promedio 0.427245 Am Acad Dermatol 0.559713 Skin biopsy 0.467836 CA Cancer 0.436346 Preventive Services Task 0.49324 Melanoma mortality following 0.47412 Instituto Nacional 0.477662 diagnosing melanoma 0.465782 Melanoma Pathology Study 0.472332 PDQ Exámenes 0.446099 malignant skin tumors 0.44617 Skin biopsy utilization 0.44782 Estados Unidos 0.486058 study comparing trends 0.42068 Skin biopsy rates 0.447638	JAMA Dermatol 0.430327 US Preventive Services 0.448303 melanoma incidence among 0.478575 Nolte S 0.427295 Rogers HW 0.427126 consecuencias adversas 0.434206 Gandini S 0.430629 estudio screen 0.45426 United States 0.464438 Arch Dermatol 0.504577 Cancer Facts 0.476716 Weinstock MA 0.509901 National Cancer Institute 0.43929 Systematic skin 0.44278 population-based screening intervention 0.428982 Services Task Force 0.491749 radiación uv 0.425917 Dermatol Surg 0.429711 systematic review 0.43149 melanoma mortality 0.579785 BMC Cancer 0.438009 malignant melanoma 0.574467 nonmelanoma skin cancer 0.673873 Lott JP 0.429356	CLICK HERE
3434	National Cancer Institute	Html	es	Té y prevención de cáncer	Hoja informativa que resume los resultados de estudios realizados sobre el té y la prevención del cáncer. Incluye información sobre los ingredientes del té y las consideraciones de seguridad sobre el consumo de esta bebida.	tea polyphenol levels 0.306381 Gynecological Cancer 0.306129 Zhang M 0.301852 té oolong 0.345261 lung cancer 0.322075 green tea extract 0.319452 case-control study 0.308604 British Journal 0.30281 Breast Cancer Research 0.324861 Human Nutrition 0.301844 verde activa enzimas 0.302661 Singapore Chinese Health 0.30349 tea polyphenol 0.33584 black tea consumption 0.317861 Inoue M 0.303594 green tea rapidly 0.307366 nested case-control study 0.302496 PubMed Abstract 0.999235 tea consumption 0.35794 Women’s Health Study 0.302821 green tea consumption 0.326657 International Journal 0.309091 Yang CS 0.303196 cohort study 0.312904 Chinese Health Study 0.305698	Hakim IA 0.303206 Drinking green 0.302093 té verdeConcentración 0.313111 Health Study 0.306628 dietary intake 0.301921 Ohsaki study 0.302059 Cancer Research 0.340725 Iwasaki M 0.30184 Shanghai Cohort Study 0.302687 prospective cohort study 0.306347 subsequent risk 0.303163 Clinical Nutrition 0.305674 breast cancer 0.401322 modestly reduces breast 0.302193 tea consumption with 0.307242 extract supplement 0.301849 Cancer Institute 0.306085 controlled study 0.301969 Clinical Cancer Research 0.312026 prospective study 0.303895 green tea polyphenols 0.325122 tea catechins after 0.306288 Netherlands Cohort Study 0.306092 té verde—500 mg 0.313535	CLICK HERE
3521	National Cancer Institute	Html	en	NCI-MATCH Trial (Molecular Analysis for Therapy Choice)	Information about the NCI-MATCH precision medicine trial, in which patients with advanced solid tumors and lymphomas are assigned to treatment arms based on the molecular profiles of their disease.	NCI-MATCH trial 0.544063 rare cancer 0.541344 COMET study 0.578429 genetic makeup 0.540259 trial 0.805751 clinical trial tracking 0.631222 usual genomic testing 0.608947 National Clinical Trials 0.604691 MATCH protocol summary 0.637152 treatment arms 0.751732 clinical trials 0.747821 newly enrolling patients 0.642185 MATCH trial 0.634351 health care professionals 0.58508 cancer care 0.539135 patients 0.983397 cancer patients 0.598511 tumor gene testing 0.590848 ECOG-ACRIN Cancer Research 0.612355 non-small cell lung 0.606702 objective response rate 0.771639 medicine cancer treatment 0.706859 genomic sequencing 0.623041 treatment arms address 0.659842	gene sequencing lab 0.599434 specific genetic change 0.644953 laboratory method 0.524995 Cancer Trials Support 0.616424 potential MATCH participants 0.636971 cancer cells 0.549314 common genetic changes 0.635293 Cancer Information Service 0.610926 clinical trial. 0.538943 genetic change 0.741928 adult trial groups 0.623508 health insurance company 0.59001 enrolled patients 0.575046 progression-free survival 0.609538 specific genetic changes 0.64881 NCI Community Oncology 0.61311 particular genetic change 0.630183 new tumor biopsy 0.621774 genetic changes 0.811113 MATCH treatment arm 0.848463 Caris Life Sciences 0.607515 NRG Oncology Group 0.586136 advanced solid tumors 0.669501 new clinical sites 0.600949	CLICK HERE